Regeneron Pharmaceuticals' Non-cash Items rose 421.26% to $158.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $493.0 million, marking a year-over-year increase of 221.10%. This contributed to the annual value of $7.9 million for FY2024, which is 98.77% down from last year.
As of Q3 2025, Regeneron Pharmaceuticals' Non-cash Items stood at $158.7 million, which was up 164.20% from -$247.2 million recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Non-cash Items ranged from a high of $1.8 billion in Q3 2021 and a low of -$2.5 billion during Q2 2021.
Its 3-year average for Non-cash Items is $72.4 million, with a median of $106.5 million in 2023.
In the last 5 years, Regeneron Pharmaceuticals' Non-cash Items plummeted by 5,462.69% in 2021 and then soared by 593.71% in 2024.
Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Non-cash Items stood at $143.5 million in 2021, then soared by 264.32% to $522.8 million in 2022, then plummeted by 113.37% to -$69.9 million in 2023, then skyrocketed by 593.71% to $345.1 million in 2024, then skyrocketed by 421.26% to $158.7 million in 2025.
Its last three reported values are $158.7 million in Q3 2025, -$247.2 million for Q2 2025, and $236.4 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value